NewsBenzingaFoghorn Therapeutics cambia su estrategia de desarrollo tras poner fin al acuerdo con Eli Lilly Foghorn Therapeutics cambia su estrategia de desarrollo tras poner fin al acuerdo con Eli Lilly Benzinga 2026.10.01 16:17 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story